Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Hard-to-Treat cancers

NCT ID NCT06697197

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BMS-986482 (an experimental drug) given alone or with nivolumab, relatlimab, or bevacizumab
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (phase 1/2) with a primary focus on safety, so it is too soon to know if the drug will work. The study is small and may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 413 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant. * Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF. Exclusion Criteria: * History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures. * Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator. * Other protocol-defined Inclusion/Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

    RECRUITING

    Marseille, Bouches-du-Rhône, 13385, France

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Erasmus Medisch Centrum

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, Lombardy, 20133, Italy

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • General Hospital of Athens "Laiko"

    RECRUITING

    Athens, Attikí, 11527, Greece

  • Gustave Roussy

    RECRUITING

    Villejuif, Paris, 94800, France

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, 28050, Spain

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, Milano, 20089, Italy

  • John Theurer Cancer Center at Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Karolinska Universitetssjukhuset Solna

    RECRUITING

    Solna, Stockholms Län [se-01], 171 64, Sweden

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Local Institution - 0008

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)

    RECRUITING

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Northwell Health/ RJ Zuckerberg Cancer Center

    RECRUITING

    Lake Success, New York, 11042, United States

  • Papageorgiou General Hospital of Thessaloniki

    RECRUITING

    Thessaloniki, Thessaloníki, 564 29, Greece

  • Rigshospitalet

    RECRUITING

    Copenhagen, Capital Region, DK-2100, Denmark

  • The Angeles Clinic and Research Institute - West Los Angeles Office

    RECRUITING

    Los Angeles, California, 90025, United States

  • UZ Gent

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    RECRUITING

    Irvine, California, 92612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.